REGENXBIO Inc.
RGNX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $30 | $21 | $89 | $21 |
| % Growth | 39.2% | -76% | 319.6% | – |
| Cost of Goods Sold | $62 | $9 | $3 | $6 |
| Gross Profit | -$32 | $12 | $86 | $15 |
| % Margin | -107.9% | 57.3% | 96.1% | 70.2% |
| R&D Expenses | $56 | $56 | $53 | $50 |
| G&A Expenses | $20 | $20 | $20 | $20 |
| SG&A Expenses | $20 | $20 | $20 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$56 | $0 | $0 | -$4 |
| Operating Expenses | $20 | $76 | $73 | $66 |
| Operating Income | -$52 | -$63 | $12 | -$51 |
| % Margin | -176.3% | -296.3% | 13.6% | -242.1% |
| Other Income/Exp. Net | -$10 | -$8 | -$6 | $0 |
| Pre-Tax Income | -$62 | -$71 | $6 | -$51 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$62 | -$71 | $6 | -$51 |
| % Margin | -208.3% | -331.8% | 6.8% | -241.3% |
| EPS | -1.2 | -1.38 | 0.12 | -1.01 |
| % Growth | 13% | -1,250% | 111.9% | – |
| EPS Diluted | -1.2 | -1.38 | 0.12 | -1.01 |
| Weighted Avg Shares Out | 52 | 51 | 51 | 51 |
| Weighted Avg Shares Out Dil | 52 | 51 | 51 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $0 | $0 |
| Interest Expense | $13 | $11 | $9 | $9 |
| Depreciation & Amortization | $4 | $4 | $4 | $4 |
| EBITDA | -$45 | -$56 | $19 | -$38 |
| % Margin | -151% | -262.1% | 20.9% | -177.9% |